University of Kansas
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From University of Kansas
The center is partnering with Obsidian to make autologous TILs work better after being infused back into patients by using IL-15, which may be less toxic than the high-dose IL-2 currently used.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2016.
The California biotech proves that an early-stage company can be just as attractive to investors as a proof-of-concept biotech if the science is strong.
Financings Of The Fortnight: Overseas Cash Holdings Don’t Mean U.S. Biopharma Lacks For Domestic Financial Opportunity
Plus news on recent financing activity by Savara Pharmaceuticals, OvaScience, TetraPhase Pharmaceuticals and Pharmacyclics.
- Academic and Research Institutions
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.